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A B S T R A C T
Objectives: Transferability of economic evaluations to low- andmiddle-
income countries through adaptation of models is important; however,
several methodological and practical challenges remain. Given its
significant costs and the quality-of-life burden to patients, adjuvant
treatment of early breast cancer was identified as a priority intervention
by the South African National Department of Health. This study
assessed the cost-effectiveness of docetaxel and paclitaxel-containing
chemotherapy regimens (taxanes) compared with standard (non-
taxane) treatments. Methods: A cost-utility analysis was undertaken
based on a UK 6-health-state Markov model adapted for South Africa
using the Mullins checklist. The analysis assumed a 35-year time
horizon. The model was populated with clinical effectiveness data
(hazard ratios, recurrence rates, and adverse events) using direct
comparisons from clinical trials. Resource use patterns and unit costs
for estimating cost parameters (drugs, diagnostics, consumables,
personnel) were obtained from South Africa. Uncertainty was assessed
using probabilistic and deterministic sensitivity analyses. Results: The
incremental cost per patient for the docetaxel regimen compared with
standard treatment was R6774. The incremental quality-adjusted life
years (QALYs) were 0.24, generating an incremental cost-effectiveness
ratio of R28430 per QALY. The cost of the paclitaxel regimen
compared with standard treatment was estimated as R578 and
R1512, producing an additional 0.03 and 0.025 QALYs, based on 2 trials.
Paclitaxel, therefore, appears to be a dominant intervention. The base
case results were robust to all sensitivity analyses. Conclusions: Based
on the adapted model, docetaxel and paclitaxel are predicted to be cost-
effective as adjuvant treatment for early breast cancer in South Africa.
Keywords: transferability, model adaptation, low- and middle-income
countries, early breast cancer
© 2019 ISPOR–The professional society for health economics and out-
comes research. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).
Introduction
Evidence from economic evaluations and broader health tech-
nology assessments (HTAs) can be useful to inform difficult
decisions in priority setting and health sector resource alloca-
tion.1,2 Globally, there has been a growth in the systematic
incorporation of economic evidence in healthcare decision
making, particularly in high-income countries (HICs). More
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recently, this trend has also been observed in low- and
middle-income countries (LMICs), where there has been a steady
growth in the number of economic evaluation studies.3-5
Nevertheless, formal structures and processes for the systematic
utilization of economic evidence to inform decision making are
less evident in these settings.6-8 This has become an important
agenda item because LMICs aim to develop equitable and
sustainable healthcare systems for delivering universal health
coverage.1,2,9
Despite an increased demand for economic evidence, LMICs
are often constrained by limited technical capacity, insufficient
resources, and poor data availability.7,10-12 The development of de
novo models for economic evaluations is both time-consuming
and expensive. This has generated an interest in the
transferability of economic evaluations through adapting
cost-effectiveness models.13
An economic evaluation is considered to be transferable if it
can be appropriately adapted for application in another setting, as
distinct from a generalizable evaluation whose results can be
applied without adjustment to other settings.14,15 A range of
approaches has been proposed for judging transferability.13,14
Nevertheless, there is limited evidence on their implement-
ability and several important methodological and practical
challenges remain, such as poor methodological and reporting
standards.13-16 Practical case studies on transferability are
therefore needed to provide pragmatic help for LMICS on
methodology and the empirical challenges in adapting economic
evaluation models from one setting to another.
Many LMICs, including South Africa, have taken practical steps
toward institutionalizing HTA for prioritizing resource allocation
in healthcare. Context-specific challenges for undertaking
economic evaluation include the quality of data and lack of local
technical capacities.12 South Africa is an upper-middle income
country moving toward universal health coverage through the
implementation of national health insurance. Although the 2018
National Health Insurance Bill cites institutionalizing HTA as a
mechanism for resource allocation decisions,17,18 the widespread
use of economic evaluation in decisionmaking in the short term is
limited by local resource and data constraints. Adapting economic
evaluation models may, therefore, be one way of circumventing
some of these challenges.
Adjuvant treatment of early breast cancer was identified as a
priority area by the South African National Department of Health
(NDoH), given the significant health and economic burden of
breast cancer in South Africa.19 Trastuzumab has recently been
adopted by the South African public system for HER2 (human
epidermal growth factor 2) amplified breast cancer20 despite its
cost-effectiveness being under debate in most LMICs.21 Early
breast cancer is defined as “breast cancer that has not spread
beyond the breast or the axillary lymph nodes. This includes
ductal carcinoma in situ and stage I, stage IIA, stage IIB, and stage
IIIA breast cancers.”22 Standard management of early breast
cancer is surgery followed by adjuvant systemic treatment with
chemotherapy or hormonal therapy, depending on the
menopausal status of the patient.20,23
South African guidelines regarding adjuvant chemotherapy
treatment recommend anthracycline-based chemotherapy
regimens for low-risk patients and a combination of taxane and
anthracycline-based chemotherapy regimens for high-risk
patients.20 Taxanes are defined as “any of various tricyclic
compounds (such as docetaxel and paclitaxel) with anticancer
activity that are obtained from yew trees (genus Taxus) or are
made synthetically.”
This article presents an economic evaluation of docetaxel and
paclitaxel-containing chemotherapy regimens compared with
standard treatments for adjuvant treatment of early breast cancer
in South Africa. Docetaxel, paclitaxel, and trastuzumab are
included in the Essential Medicines List in South Africa. The
analysis was based on an economic model originally developed in
an HIC (UK),24 which we adapted for the upper-middle income
country setting of South Africa. We also outline our findings
regarding the appropriateness and practicality of existing model
adaptation methods using this decision problem as a case study.
Methods
Overview
A cost-utility analysis was undertaken to assess the cost-
effectiveness of docetaxel and paclitaxel-containing chemo-
therapy regimens (taxanes) compared with non-taxane standard
regimens for adjuvant treatment of early breast cancer in South
Africa. The analysis was based on a Markov model (originally
developed in the UK) and further adapted in this study for use in
South Africa. The analysis took a South African public health
system perspective over a 35-year time horizon. A longer time
horizonwas considered unnecessary based on life tables for South
Africa.25 Outcomes were assessed in quality-adjusted life-years
(QALYs) and resource use costs were assessed in South African
rand at 2017 values. Both QALYs and costs were discounted at 5%
per year as recommended by the NDoH in South Africa.26
Model Adaptation Methods
Eight model adaptation methods were identified from an existing
systematic review13 supplemented by a citation search of key
papers13,27,28 using Web of Science and Scopus databases. The
methods thus identified14,16,29-34 were then appraised against
criteria developed by the authors. The criteria were: (1) relevance
(needed to be specifically about model adaptation), (2) endorse-
ment from a respected organization (eg, International Society for
Pharmacoeconomics and Outcomes Research, International
Health Economics Association), (3) compatibility with the
International Decision Support Initiative's reference case for
economic evaluation35 (ie, do address the 11 methodological
principles outlined in the International Decision Support Initiative
reference case?), (4) transparency (ie, is there an explanation of
how the method was developed?), (5) inclusiveness (ie, was the
method used to develop the checklist comprehensive? automati-
cally “no” if no explanation given), (6) practicalitydlength (shorter
is better), (7) external validitydtested in case studies, and (8)
external validitydtested in case studies in LMICs.36 A traffic light
system was used in relation to whether each method met the
appraisal criteria, with 3 options: yes (green), partially (orange),
and no (red) (see Appendix Tables 1 and 2 in Supplemental
Materials found at https://doi.org/0.1016/j.vhri.2019.03.003).36
Based on this appraisal and after discussion with the wider
team of the relative merits of each of the methods, the Mullins
checklist was chosen as the most appropriate guide to the model
adaptation process (see Appendix 2 in Supplemental Materials
found at https://doi.org/0.1016/j.vhri.2019.03.003).
Model Structure
The analysis was based on an existing six-health-state Markov
model,24 which was adapted using the Mullins checklist.16 The
model structure (Fig. 1) illustrates the 6 different health states
used and how a patient moves from one to another. The health
states modeled were (1) disease-free survival, (2) locoregional or
contralateral relapse, (3) metastatic disease, (4) remission,
(5) death from breast cancer, and (6) death from other causes. No
structural changes were made to the model. All patients start in
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the disease-free survival state after adjuvant treatment. A patient
then transitions to one of 3 possible states: first, locoregional,
contralateral relapse, or metastatic disease; second, death from
other causes (not breast cancer related); or third, the patient
remains in the disease-free survival health state. From
locoregional or contralateral relapse, a patient transitions into
remission, metastatic disease, or death from other causes. The
metastatic disease state is an absorbing state: a patient remains in
it, dies from breast cancer, or dies from other causes. A patient in
the remission state will remain in that state, transition to
metastatic disease, or die from other causes.
The cycle length in the model was 1 year, and half-cycle
correction was applied to take into account the differences in
timing of events within each cycle. The model derives the
Figure 1 – Model structure and adjuvant treatment pathways for early breast cancer in South Africa.
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Table 1 – Model parameters
Parameter Value Distribution Updated/replaced with
data from South Africa
(N/Y)
General parameters
Time horizon 35 years NA N
Cycle length 1 year NA N
Start age 50 years NA N
Discount rate (QALYs) 5% NA Y
Discount rate (costs) 5% NA Y
HRs
DAC vs FAC (based on BCIRG
001)
0.71 (95% CI: 0.58-0.87) Log-normal N
ACP vs AC (based on NSABP
B28)
0.82 (95% CI: 0.72-0.94) Log-normal N
ACP vs AC (based on CALGB
9344)
0.83 (95% CI: 0.73-0.94) Log-normal N
DAC vs FAC, 10-year follow-
up based on BCIRG 001
(used in sensitivity
analysis)
0.80 (95% CI: 0.68-0.93) Log-normal Y
Type of recurrence in taxane arm based on trials
DAC (based on BCIRG 001) Local, 19%
Contralateral, 5%
Distant, 76%
Dirichlet N
ACP (based on NSABP B28) Local, 29%
Contralateral, 5%
Distant, 66%
Dirichlet N
ACP (based on CALGB 9344) As for NSABP B28 Dirichlet N
Type of recurrence in comparator arm
FAC (based on BCIRG 001) Local, 19%
Contralateral, 4%
Distant, 77%
Dirichlet N
AC (based on NSABP B28) Local, 32%
Contralateral, 7%
Distant, 61%
Dirichlet N
AC (based on CALGB 9344) As for NSABP B28 Dirichlet
Annual probability of metastatic disease in patients with locoregional or contralateral recurrence
Year 1 0.18 (95% CI: 0.12 to 0.25) Beta N
Year 2 0.19 (95% CI: 0.13 to 0.27) Beta N
Year 3 0.12 (95% CI: 0.06 to 0.19) Beta N
Year 4 0.09 (95% CI: 0.04 to 0.16) Beta N
Year 5 and beyond 0.12 (95% CI: 0.05 to 0.20) Beta N
Annual probability of death in patients with metastatic disease
Each year 0.37 (95% CI: 0.32-0.43) Beta N
Quality of life multipliers for health states
Disease free 0.940 (SE ¼ 0.11) Beta N
Ipsilateral recurrence 0.740 (SE ¼ 0.26) Beta N
Contralateral recurrence 0.740 (SE ¼ 0.26) Beta N
Metastatic recurrence 0.500 (SE ¼ 0.196) Beta N
Remission 0.850 (SE ¼ 0.196) Beta N
Drug costs (including administration cost)
Comparator regimen (FAC) R9477 Fixed Y
Comparator regimen (AC ) R5338 Fixed Y
Docetaxel regimen (DAC) R15 928 Fixed Y
Paclitaxel regimen (ACP)
based on NSABP B28 trial
regimen
R8252 Fixed Y
Paclitaxel regimen (ACP)
based on CALGB 9344 trial
regimen
R7633 Fixed Y
AE cost in taxane arm
Febrile neutropenia (DAC) R16 092 (LUB: 12 069-20 115) Gamma Y
Febrile neutropenia (ACP) R15 163 (LUB: 11 373-18 954) Gamma Y
Diarrhea R176.25 (LUB: 132-220) Gamma Y
Vomiting R176.91 (LUB: 132-221) Gamma Y
continued on next page
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probabilities of patients moving between health states from
clinical trials.16,37-39 Some probabilities, such as those for
disease-free survival and locoregional or contralateral relapse,
depend on the initial and follow-up treatments (comparator or
taxane treatment) received. Other probabilities relating to death
or transition to metastatic disease are assumed to be the same in
both the comparator and taxane treatment regimens
Evidence Used to Inform the Model Parameters
Model parameters, including mean estimates, 95% confidence
intervals (CIs), distributions assigned, and sources of evidence are
presented in Table 1. Based on estimates from clinical trials,38,39
women were assumed to enter the model aged 50 years.
Evidence for estimating clinical effectiveness, health-related
quality of life, mortality rates, and costs is presented in the
following subsections.
Clinical Effectiveness
The interventions and comparators assessed are (1) docetaxel
regimen: doxorubicin (Adriamycin) 50 mg/m2 intravenous (IV)
infusion for 15minutes followed by cyclophosphamide 500mg/m2
IV for 1 to 5minutes, after a 1-hour interval docetaxel 75mg/m2 IV
infusion for 1 hour, 6 21-day cycles (DAC), compared with
50mg/m2 of doxorubicin, followed by 500mg/m2 of fluorouracil as
IV infusion for 15 minutes, then 500 mg/m2 IV infusion of
cyclophosphamide for 1 to 5 minutes, 6 21-day cycles (FAC); and
(2) paclitaxel regimen: 60 mg/m2 of doxorubicin, 600 mg/m2 of
cyclophosphamide, 4 3-week cycles, followed by paclitaxel
225 mg/m2 3-hour infusion, 4 3-week cycles (ACP) compared
with 60 mg/m2 of doxorubicin, 600 mg/m2 of cyclophosphamide,
4 3-week cycles (AC).40
Clinical effectiveness estimates (including hazard ratios (HRs),
transition probabilities, and adverse events) came from 3 clinical
trials that compared these interventions in head-to-head
experimental designs. The BCIRG (Breast Cancer International
Research Group) 001 trial39 compared DAC and FAC regimens;
National Surgical Adjuvant Breast and Bowel Project (NSABP)
B-2838 and Intrinsic Breast Cancer Subtypes and Benefit of
Paclitaxel (CALGB)-934437 both compared ACP with AC regimens.
The BCIRG 001 study was a multinational study with participants
from 20 countries including South Africa. The distribution of
breast cancer stages in these trials is published elsewhere.24 The
cyclophosphamide, methotrexate, fluorouracil regimen was in
current use in South Africa but was excluded from the analysis for
2 main reasons: first, its current use is, we understand, limited to
small regions, and second, a direct comparison for this regimen
was not found in the literature review.
To update the clinical effectiveness evidence used to populate
the original model, the MEDLINE database was searched for
clinical trials published between 2005 and 2017. Trials were
included if they reported any of the interventions assessed (DAC,
ACP) with similar dosing regimens as reported in Ward et al.24
Studies were also included if they reported any of the
comparators assessed in this study (AC, FAC). The outcome
measures of interest include disease-free survival and type of
recurrence (contralateral breast cancer, distant recurrence, or
Table 1 – continued
Parameter Value Distribution Updated/replaced with
data from South Africa
(N/Y)
Stomatitis R176.91 (LUB: 132-221) Gamma Y
Blood transfusion R1605.60 (LUB: 1204-2007) Gamma Y
Allergy R1401.87 (LUB: 1051-1752) Gamma Y
AE cost in comparator arm if different
Febrile neutropenia: FAC R16 092 (LUB: 12 069-20 115) Gamma Y
Febrile neutropenia: AC R15 163 (LUB: 11 373-18 954) Gamma Y
Chemotherapy for locoregional/contralateral recurrence (additional following local recurrence)
Comparator arm (FAC) R28 430 (LUB: 21 322-35 537) Gamma Y
Comparator arm (AC) R17 650 (LUB: 13 237-22 062) Gamma Y
Taxane arm (DAC) R4778 (LUB: 3584-5973) Gamma Y
Taxane arm (ACP): based on
NSABP B28 trial regimen
R2476 (LUB: 1857-3095) Gamma Y
Taxane arm (ACP): based on
CALGB 9344 trial regimen
R2290 (LUB: 1717-2862) Gamma Y
Health state costs
Disease free R2663 (LUB: 1997-3329) Gamma Y
Ipsilateral recurrence R37 134 (LUB: 27 851-46 418) Gamma Y
Contralateral recurrence R37 134 (LUB: 27 851-46 418) Gamma Y
Metastatic recurrence R15 726 (LUB: 11 794-19 657) Gamma Y
Remission (no costs after
5 years)
R2538 (LUB: 1904-3173) Gamma Y
Death due to breast cancer R41 173 (LUB: 30 880-51 466) Gamma Y
Disease-free survival
>5 years
R1430 (LUB: 1072-1787) Gamma Y
Cost from 5 years after
remission
R1413 (LUB: 1060-1766) Gamma Y
AC indicates doxorubicin (Adriamycin), cyclophosphamide; ACP, doxorubicin, cyclophosphamide, paclitaxel; DAC, docetaxel, doxorubicin,
cyclophosphamide; FAC, fluorouracil, doxorubicin, cyclophosphamide; HR, hazard ratio; LUB, lower and upper bound; NSABP, National Surgical
Adjuvant Breast and Bowel Project; QALYs, quality-adjusted life-years; N, no; Y, yes.
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local/regional recurrence). Evidence from 10 years’ follow-up for
docetaxel41 was identified and used in the analysis (see Appendix
3 in Supplemental Materials found at https://doi.org/0.1016/j.
vhri.2019.03.003).
Health-Related Quality of Life
Health state utilities used in the original model mainly came from
a systematic review of publicly available source documents.42 To
account for the decrease in health-related quality of life with age,
general population values were applied using a regression
analysis of utility versus age.24 Patients enter the model at age 50
years with an age-related utility of 0.85, and their utility is
estimated to decline by 0.04 per 10-year increase in age. The
utilities for all health states were multiplied by the age-related
utility value for each year cycle in the model. To update the
utility data, a searchwasmade of the School of Health and Related
Research health utility database, the Tufts Cost-Effectiveness
Analysis database, and recent National Institute of Clinical
Excellence Appraisals.43 These searches found, however, no
relevant updates to UK or South Africa specific utility values for
the modeled health states (see Appendix 4 in Supplemental
Materials found at https://doi.org/0.1016/j.vhri.2019.03.003 for full
results of the review).
Mortality Rates
Mortality rates for women by age group in South Africa came from
the World Health Organization’s Global Health Observatory Data
repository.25 All mortality rates used in the original model were
replaced by South African-specific mortality rates as part of the
model adaptation process (see Appendix 4 in Supplemental
Materials found at https://doi.org/0.1016/j.vhri.2019.03.003).
Costs
Cost estimates were based on specific South African data from
document reviews, expert opinion, and national reference unit
costs (see Appendix 5 in Supplemental Materials found at
https://doi.org/0.1016/j.vhri.2019.03.003). Documents reviewed
included the NDoH’s basic breast cancer package, its Master
Procurement Catalogue, and a draft version of the NDoH’s breast
cancer guidelines. Three clinicians from the Expert Review
Group were consulted. The Expert Review Group provides
recommendations on revisions of the Essential Medicines List and
the Standard Treatment Guidelines. The clinical experts provided
information on current clinical practice for treatments and
management of early breast cancer in South Africa.
Resource use estimates such as treatments, diagnostics,
consumables, personnel, and time required were identified for
each activity performed for adjuvant treatment and for each
health state in the model. Information from experts was
incorporated into data sourced from the 3 core documents listed
above and applied to estimate specific South African cost
parameters. An overview of the clinical pathways with all
resource use identified and included in estimating cost
parameters is given in Figure 1. Unit costs for docetaxel and
paclitaxel were based on the Master Procurement Catalogue. Both
products were generics.44 The detailed cost data including drug
costs, therapy administration costs, resource associated with
each health state, and adverse event costs are provided as
supplementary material (see Appendix 5 in Supplemental
Materials found at https://doi.org/0.1016/j.vhri.2019.03.003).
Cost-Effectiveness Threshold
This study uses a South Africa-specific cost-effectiveness
threshold, which attempts to capture the true opportunity costs of
resource allocation decisions. Cost-effectiveness thresholds
based on opportunity costs are derived indirectly from estimates
of the marginal effects of health expenditures on mortality.45-47
Woods et al 201647 indirectly estimated a cost per QALY
threshold for several countries (including South Africa) using a
previously estimated opportunity cost-based threshold for the
UK39 weighted by each country’s income (gross domestic product
per capita) and income elasticity for the value of a statistical life.
Using this approach, Woods et al estimated a cost per QALY
threshold of $1175 to $4714 for South Africa. This is equal to
R15 630 to R62 700 (16%-63% of South Africa’s gross domestic
product per capita), which was calculated using an exchange rate
of 13.3 South African rand per $1.00 in base year 2017. This
threshold was used as the benchmark for assessing the
cost-effectiveness of docetaxel and paclitaxel in South Africa.
Cost-Effectiveness Analysis
Our cost-utility analysis was based on the adapted model using
pairwise comparisons of taxanes versus usual care comparators.
The results were expressed as incremental costs per QALY gained.
Robustness was assessed using both probabilistic sensitivity
analysis (PSA) and 1-way deterministic sensitivity analysis (DSA).
The PSA was run on 10000 Monte Carlo simulations, and the
results were generally stable at 10 000 iterations. The DSA
explored parameters where more uncertainty was anticipated.
This included 10-year disease-free survival HR and recurrence
rates based on a long-term follow-up from the BCIRG 001 trial,
using the Department of Public Service and Administration unit
costs for drugs and health states, applying a 1.5% discount rate for
QALYs, and assuming no cost for granulocyte colony-stimulating
factor following febrile neutropenia.
Results
Base-Case Estimates of Cost-Effectiveness
The base-case estimates of cost-effectiveness using average
estimates from the 10000 runs of the PSA are presented in Table 2.
This shows the incremental mean costs per patient, incremental
mean QALYs, incremental cost-effectiveness ratio or dominance,
and the probability of cost-effectiveness at the lower and upper
bound of the cost-effectiveness threshold for South Africa.
Docetaxel
The probabilistic ICER for the docetaxel regimen (DAC) compared
with the non-taxane regimen (FAC) was estimated at R28 483 per
QALY gained. It was generated from an incremental mean cost of
R6774 per patient and incremental mean QALYs per patient of
0.24 (see Table 2). This result suggests that a docetaxel-containing
chemotherapy regimen is cost-effective at the upper bound of the
cost-effectiveness threshold (R62 700 per QALY) with 0.93
probability of cost-effectiveness. Nevertheless, docetaxel is
unlikely to be cost-effective at the lower bound of the threshold
(R15 630 per QALY)dthe probability of cost-effectiveness is only
0.04.
The cost-effectiveness acceptability curve in Figure 2 shows the
probability that docetaxel is cost-effective for a range of
cost-effectiveness thresholds. Figure 3 shows the net monetary
benefit (NMB) for 1000 women over the analysis time horizon using
both the lower and upper bound of the cost-effectiveness threshold.
As shown in the Figure, the NMB starts off with a negative value up
to a point around year 7 and then gradually becomes positive up to
R8.3 million over 35 years using the upper bound of the threshold.
Nevertheless, at the lower bound of the threshold, the NMB
remained negative over the analysis time horizon.
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Paclitaxel
The results show that paclitaxel regimen (ACP) is dominant versus
non-taxane (AC) because it is both less costly and more effective.
The estimated difference in mean cost per patient was R578 and
R1512, generating 0.03 and 0.025 QALYs based on NSABP and
CALGB trials, respectively. The probability of cost-effectiveness is
0.86 and 0.74 at the R15 630 threshold. At the upper bound of the
threshold, the probability of cost-effectiveness increases to 0.96
and 0.9. Figure 4 shows the NMB results based on the NSABP B-28
trial. As shown in the Figure, the paclitaxel regimen has a positive
NMB beyond the 7-year time horizon, when both upper and lower
bounds of the cost-effectiveness threshold are considered,
although the magnitude of benefit is higher when the upper
bound is considered. Paclitaxel results based on the CALGB-9344
trial produced approximately similar NMB results (Table 2).
Sensitivity Analysis Results
The results from the DSAs on the base-case ICER estimates show
the high robustness of our primary cost-effectiveness estimates in
all the sensitivity analyses performed. Using updated clinical
effectiveness evidence for docetaxel (HR and recurrence rates over
a 10-year follow-up) did not change the base-case results. Ignoring
the cost for granulocyte colony-stimulating factor following
febrile neutropenia reduced the ICER for the DAC regimen
compared with FAC to R11 899 per QALY gained. All results from
the sensitivity analysis performed are provided as supplementary
material (see Appendix 6 in Supplemental Materials found at
https://doi.org/0.1016/j.vhri.2019.03.003).
Discussion
Using resource cost data from South Africa, combined with
effectiveness evidence from clinical trials, the analysis suggests
that docetaxel and paclitaxel regimens are both cost-effective
interventions given the postulated South African threshold. A
docetaxel regimen (DAC) has an incremental cost per QALY of
R28 483 compared with a non-taxane chemotherapy regimen
(FAC). A paclitaxel regimen (ACP) is dominant (lower cost and
Table 2 – Base-case estimates of cost-effectiveness
Analysis Incremental
Cost
Incremental
QALYs
ICER (rand per
QALY gained)
Probability of cost-effectiveness at R15630
(R62700) threshold
Docetaxel based on BCIRG 001
trial (DAC vs FAC)
R6774 0.238 28483 0.04 (0.93)
Paclitaxel based on NSABP B-28
trial (ACP vs AC)
R578 0.030 Dominant 0.86 (0.96)
Paclitaxel based on CALGB 9344
trial (ACP vs AC)
R1512 0.025 Dominant 0.74 (0.90)
AC indicates doxorubicin (Adriamycin), cyclophosphamide; ACP, doxorubicin, cyclophosphamide, paclitaxel; FAC, fluorouracil, doxorubicin,
cyclophosphamide; DAC, docetaxel, doxorubicin, cyclophosphamide; ICER, incremental cost-effectiveness ratio; NSABP, National Surgical
Adjuvant Breast and Bowel Project; QALYs, quality-adjusted life-years.
Figure 2 – Cost-effectiveness acceptability curve of docetaxel regimen (DAC vs FAC) based on BCIRG 001 trial.
BCIRG indicates Breast Cancer International Research Group; DAC, docetaxel, doxorubicin, cyclophosphamide; FAC,
fluorouracil, doxorubicin, cyclophosphamide.
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greater benefit) compared with an AC regimen. Docetaxel has a
0.93 probability of cost-effectiveness at the upper bound of the
cost-effectiveness threshold (R62 700 per QALY). Nevertheless,
docetaxel was not cost-effective at the lower bound of
cost-effectiveness threshold (R15 630), where the probability of
cost-effectiveness was estimated as 0.04. The primary
cost-effectiveness results were robust in all sensitivity analyses.
Although the HR for recurrence was lower for docetaxel based
on BCIRG 001 trial compared with paclitaxel (based on the 2 trials,
NSABP B-28 and CALGB 9344), paclitaxel showed better
cost-effectiveness results. This is largely due to the lower price of
(generic) paclitaxel in South Africa (R7633-R8252) compared with a
generic docetaxel cost of R15 928 for all cycles specified by the
regimens used in these trials. This is contrary to results from the
Figure 3 – Net monetary benefit of docetaxel regimen (DAC vs FAC) in 1000 women based on BCIRG trial.
BCIRG indicates Breast Cancer International Research Group; DAC, docetaxel, doxorubicin, cyclophosphamide; FAC,
fluorouracil, doxorubicin, cyclophosphamide.
Figure 4 – Net monetary benefit of paclitaxel regimen (ACP vs AC) in 1000 women based on NSABP B28 trial.
AC indicates doxorubicin (Adriamycin), cyclophosphamide; ACP, doxorubicin, cyclophosphamide, paclitaxel; NSABP,
National Surgical Adjuvant Breast and Bowel Project.
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original model used in the UK where paclitaxel was not
cost-effective, having a higher estimated ICER of £43 000 per QALY
gained (Range: £16 000-dominated). This was due to the difference
in cost of paclitaxel and docetaxel as well as the difference in
outcome.
For paclitaxel, the difference in the outcome between the UK
model and our adapted model can be attributed to the difference
in discount rates, among other factors. These factors include the
difference in mortality rates with more patients dying earlier in
the South African model compared with the UKmodel. This led to
a reduced benefit in the longer term. For example, in the UK
model, the incremental QALYs for paclitaxel was 0.14; in the
South African model this was reduced to only 0.03. In the adapted
model, we have included the annual probability of death in
patients withmetastatic cancer (breast cancer deaths), which was
not replaced with data from South Africa, because we had no new
data. In addition, the South African specific mortality rates (death
from other causes) for women by age group were used in the
adapted model.
The time horizon is a key influence on cost-effectiveness. The
costs of the taxane-chemotherapy regimen are incurred in the
first few months, whereas QALY benefits due to reduced
recurrence occur in the medium to long-term. Reducing the time
horizon of the analysis to 5 years (trials follow-up) produces
negative cost-effectiveness results in NMB. With a 7-year time
horizon, the NMB becomes positive as the accumulated benefits
start to offset the higher costs incurred in the first few months.
The NMB accumulates to a higher value of about R8 million for
docetaxel and R2.5 to R3.0million for paclitaxel per 1000women at
around the 20-year time horizon. After this point, no significant
gains in NMB are expected for either regimen up to a modeled
time horizon of 35 years.
Among the strengths of this work is that it was based on a
well-validated model, which was adapted from the UK to South
Africa using the Mullins checklist. The analysis was based on
resource use and cost data collected from the South African
health care system, supplemented by our review of evidence
from the literature43 and further informed by clinical experts.
The analysis was also informed by updated clinical effectiveness
evidence. This increased our confidence in the cost-effectiveness
results.
The most significant limitation of this case study was the lack
of specific South African data on clinical effectiveness and health
state transition probabilities. It may be that clinical effectiveness
evidence is largely transferable between jurisdictions14; however,
this assumption may not hold in this case because breast cancer
prognosis has been shown to differ between ethnic groups.
Whereas differential effectiveness can be estimated via subgroup
analyses or metaregression, this was impossible in our study
owing to the lack of comparability between the trial participants
and South African ethnic groups.
Specific updated South African data on health state utilities
were also lacking. Although several comparisons of utility values
and tariffs across HICs are available (eg, Heijink et al48 and Olsen
et al49), differences between high- and low-income countries have
rarely been investigated. The comparisons across HICs have
shown mixed results relating to preference heterogeneity and
methodological differences.48,49 Salomon et al50 compared Global
Burden of Disease disability weights for Bangladesh, Indonesia,
Peru, and Tanzania and concluded that across different cultural
environments there was “strong evidence of highly consistent
results.” Although the use of utility values from another country
will undoubtedly increase uncertainty, it is difficult to identify any
systematic bias that it may introduce.
No available updates in our literature review were relevant to
South Africa. Research budget constraints made it necessary
to rely on the expert opinion of oncologists for data relating to
clinical practice. There is no universally accepted best practice in
South Africa that can be used as the baseline; however, this may
change with current work done with the National Health
Insurance Authority. The cost-effectiveness threshold used has a
considerable range, which makes it a far from unambiguous test
(ie, 4% to 93% chance of cost-effectiveness using the lower and
upper bounds, respectively).
It was a great advantage from the modeling perspective that
technologies of interest such as taxanes are already used in
clinical practice in South Africadso here there were more data
available, especially for drug costs. Nevertheless, clinical practice
did notmatch themodel directly, especially in cycle length, which
did not reflect actual practice in South Africa. This is likely to have
implications for the estimated total costs and cost-effectiveness
of the interventions. Nonetheless, the findings of this study
could be used to inform future adoption decisions by considering
the cost-effectiveness of all alternative options.
Model adaptation from HICs to LMICs is possible, but it is not
easy and may need considerable resources. We spent much more
time than originally anticipated. A major need for subsequent
studies of taxanes in South Africa is the estimation of health state
utilities and clinical effectiveness. Adaptation is certainly easier
when clinical practices and cultural conditioners are not too
heterogeneous across the countries being compared and where
the models used in the source material are not too antiquated.
Conclusions
Based on model adaptation and using resource cost data from
South Africa, docetaxel and paclitaxel-containing chemotherapy
regimens are predicted to be cost-effective interventions
compared with standard treatments as adjuvant treatment for
early breast cancer. Model adaptation from HICs to LMICs is
possible but not easy and may be context and decision specific.
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